Abstract The interleukin-6 (IL-6) inhibitors tocilizumab and sarilumab have been repurposed for COVID-19 treatment. However, discrepancies exist across global and national COVID-19 guidelines, with limited data on the comparative effectiveness between these therapeutics especially during the delta/omicron periods.
Amelia Green
Get in touch with Amelia
Contact Amelia, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack